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Background: Leukaemic patients receiving intensive chemotherapy and patients undergoing autologous stem-cell transplanta-
tion (ASCT) are routinely screened for oral foci of infection to reduce infectious complications that could occur during therapy.
In this prospective study we assessed the effect of leaving chronic oral foci of infection untreated on the development of infectious
complications in intensively treated haematological patients.
Methods: We included and prospectively evaluated all intensively treated leukaemic patients and patients undergoing ASCT
who were referred to our medical centre between September 2012 and May 2014, and who matched the inclusion/exclusion
criteria. Acute oral foci of infection were removed before chemotherapy or ASCT, whereas chronic oral foci were left untreated.
Results: In total 28 leukaemic and 35 ASCT patients were included. Acute oral foci of infection were found in 2 leukaemic (7%) and
2 ASCT patients (6%), and chronic oral foci of infection in 24 leukaemic (86%) and 22 ASCT patients (63%). Positive blood cultures
with microorganisms potentially originating from the oral cavity occurred in 7 patients during treatment, but were uneventful on
development of infectious complications.
Conclusions: Our prospective study supports the hypothesis that chronic oral foci of infection can be left untreated as this does
not increase infectious complications during intensive chemotherapy.
Patients diagnosed with acute myeloid leukaemia (AML), acute
lymphoblastic leukaemia (ALL), multiple myeloma (MM), non-
Hodgkin’s lymphoma (NHL) or Hodgkin’s lymphoma (HL) are
usually treated with high-dose chemotherapy upfront or in a
salvage setting. High-dose chemotherapy causes severe neutropenia
(absolute neutrophil count o500 per ml) for a certain period of
time, which puts patients at high risk of infections, sepsis and
septic shock (Walsh, 2010). Patients undergoing high-dose
chemotherapy are also prone to develop oral side effects such as
oral mucositis, oral dryness, taste changes, and local and systemic
infections (Brennan et al, 2010). Both neutropenia and oral
mucositis significantly increase the risk for infectious complica-
tions during chemotherapy in these patients.
Haematologic patients subjected to high-dose chemotherapy are
routinely screened for oral foci of infection before starting intensive
treatment, as oral foci of infection may cause complications during
treatment. Acute exacerbation of oral foci of infection is presumed
to result in bacterial translocation from the oral cavity to the blood.
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To minimise the risks of developing oral problems and to reduce
the chance of developing neutropenic fever, oral foci of infection,
which are anticipated to cause problems during chemotherapy, are
routinely eliminated. In our hospital, a team of oral maxillofacial
surgeons, hospital dentists and dental hygienists screen the patients
for oral foci of infection before the onset of cancer therapy.
It is still unclear which specific oral disorders have to be
considered as an oral focus of infection in high-dose chemotherapy
patients, which is also the case in head and neck radiotherapy
(Schuurhuis et al, 2015). Furthermore, the oral side effects of
chemotherapy are essentially temporary and reversible, so the risk
of developing complications due to oral foci of infection is not
higher than in healthy subjects once patients have recovered from
chemotherapy (Stokman et al, 2008). This is in contrast to head
and neck radiotherapy, where the risk of oral foci of infection
causing severe morbidity (like osteoradionecrosis) remains high or
even increases after completion of radiotherapy (Vissink et al,
2003). Thus, the efficacy of dental screening for oral foci of
infection in high-dose chemotherapy patients is questionable.
Moreover, leukaemic patients usually have to start chemother-
apy shortly after diagnosis. Consequently, if oral foci of infection
are found during pre-treatment dental screening, insufficient time
is available for effective dental treatment before starting
chemotherapy. The decreased healing capacity during the phase
of untreated leukaemia is also a factor.
Following intensive chemotherapy, leukaemic patients are
expected to experience severe neutropenia for at least 3 weeks,
with episodes of neutropenic fever and relatively mild oral
mucositis, whereas patients subjected to autologous stem-cell
transplantation (ASCT) are expected to experience severe neu-
tropenia for 1–2 weeks, but with a considerably higher chance of
severe oral mucositis (Blijlevens et al, 2008). Both leukaemic
patients and patients treated with high-dose chemotherapy
followed by ASCT were included in this study, because the effects
of an oral focus of infection and pre-chemotherapy dental
treatment might be different due to the difference in duration of
neutropenia and severity of oral mucositis between these groups.
Previous studies had mixed patient groups and/or a small number
of patients (Toljanic et al, 1999; Melkos et al, 2003) or reported on
the need for treatment of postendodontic asyptomatic periapical
radiolucencies (Peters et al, 1993).
This prospective study tested the hypothesis that chronic oral
foci of infection do not have to be eliminated before intensive
chemotherapy in leukaemic patients subjected to intensive
chemotherapy and MM/NHL/HL patients subjected to high-dose
chemotherapy and ASCT. An oral focus of infection was
considered chronic if that focus had not exacerbated during the
previous 3 months.
MATERIALS AND METHODS
Patients. All patients diagnosed with AML or ALL before
remission-induction chemotherapy and patients diagnosed with
NHL/HL or MM before high-dose chemotherapy and ASCT, who
were referred to the University Medical Center Groningen between
September 2012 and May 2014, and who met the inclusion criteria,
were included in this study. The medical ethical committee of the
University Medical Center of Groningen approved our study
protocol (METC 2012/170). Patients with AML were treated with
Cytarabine (Ara-C)-based chemotherapy combined with anthracy-
cline. Patients with ALL were treated with intensive chemotherapy
according to HOVON-100 and HOVON-71 study protocols
(Daenen et al, 2012). The NHL/HL patients were treated with
BEAM and ASCT (Holmberg and Maloney, 2011; Martin et al,
2015) and MM patients with high-dose melphalan (100mgm 2
on days  3 and  2) before ASCT (Engelhardt et al, 2014).
BEAM is a combination of carmustine, etoposide, cytarabine and
melphalan.
Patients were included in this study if a pre-chemotherapy/pre-
ASCT dental screening was done in the UMCG, if they were
fully or partially dentate and were 418 years. Patients were
excluded if they were not treated according to the study protocol
on the treatment of acute and chronic oral foci.
Dental screening. Standard dental screening consisted of the
following:
 Intra-oral screening for mucosal and dental pathologies.
 Panoramic radiograph and periapical dental radiographs when
indicated, for example, when apical problems were suspected on
the panoramic radiograph or other abnormalities were seen.
 Periodontal examination including probing pocket depth
measurements, gingival recession, mobility and furcation
measurements. Plaque and bleeding scores were assessed as a
percentage of the total number of sites with plaque, respectively,
bleeding on probing. To quantify periodontal disease,
the periodontal inflamed surface area (PISA) was used (Nesse
et al, 2008).
 Inquiry about oral health maintenance and the number of
annual dental visits.
In addition, a baseline throat swab and subgingival samples were
taken during the dental screening.
Elimination of oral foci of infection. Acute oral pathology and/or
teeth causing pain or other symptoms were eliminated pre-
chemotherapy, whereas chronic oral foci were not eliminated
preceding the chemotherapy based on the study by Toljanic et al
(1999).
Data sampling before and during chemotherapy. On the first
day of hospitalisation and before the start of chemotherapy, throat
and rectal swabs were collected. Subsequent throat and rectal swabs
were taken weekly during hospitalisation (standard care). Haema-
tology nurses daily checked the oral cavity for oral mucositis,
according to the WHO mucositis grading scale (Sonis et al, 2004).
Standard care during chemotherapy. All included patients
hospitalised for high-dose chemotherapy were given selective
digestive decontamination (SDD) therapy consisting of oral
amphotericin B or fluconazole, colistine, and/or trimethoprim/
sulfamethoxazole or ciprofloxacin (Silvestri et al, 2007; Silvestri
et al, 2009). During fever (body temperature X38.5 1C), irrespec-
tive of the neutropenic status of the patient, blood cultures and
central line cultures were taken, and after which a piperacilline/
tazobactam therapy was started. Radiography of the lungs was
performed to exclude pneumonia. Urine cultures were taken.
Clostridium difficile colitis was excluded. The patients were
physically examined by the haematologist or internal medicine
physician on a daily basis, and additional blood cultures were taken
after 48–72 h of fever.
Oral care and oral problems during chemotherapy. All patients
were advised to continue normal daily oral care (tooth brushing
and/or interdental cleaning) as long as possible. In addition, or
when brushing was too painful, patients were advised to rinse the
oral cavity with saline solution four times per day and not to wear
their removable prosthesis, if any, during chemotherapy courses.
ASCT patients were seen by the dental hygienist for oral
examination three times per week during their hospital admission.
Leukaemic patients were seen by the dental hygienist when oral
complaints had developed.
If untreated, chronic oral foci of infection became acute during
chemotherapy, or between chemotherapy courses, piperacilline/
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tazobactam was given and appropriate dental treatment was
rendered.
Follow-up after treatment. Patients were followed during the
course of their haematologic treatment up until 6 weeks after
treatment had ended. Patient charts were reviewed for oral
problems during and after treatment. After treatment had ended,
patients were seen weekly by the haematologist for check-ups at the
outpatient haematology department.
Microbiological sampling and analysis. To determine the
possible oral origin of microorganisms found in blood cultures,
bacteriological samples were taken and compared with the results
of blood cultures.
A throat swab of the tonsil area was taken according to the
method described by Syed and Loesche (1972). Microbiological
analysis of throat swabs was performed according to the standard
procedures, and included detection of yeasts, Staphylococcus aureus
and aerobic Gram-negative rods. Aerobic incubation took place for
48 h at 35 1C.
Periodontal (subgingival) samples were taken from the deepest,
bleeding or suppurating pocket in each quadrant of the dentition.
Two sterile paper points were inserted to the depth of the pockets,
left in place for 10 s and were collected and pooled in 2ml of
reduced transport fluid (Syed and Loesche, 1972). Periodontal
samples were processed using culturing technique as described by
van Winkelhoff et al (1985) and van Steenbergen et al (1993).
Anaerobic cultivation was performed to determine the total
periodontal bacterial load and presence and levels of Aggregati-
bacter actinomycetemcomitans, Porphyromonas gingivalis, Prevo-
tella intermedia, Tannerella forsythia, Fusobacterium nucleatum,
Parvimonas micra and Campylobacter rectus. If Gram-negative
aerobic rods or staphylococci were found in positive blood cultures,
periodontal samples were also analysed for the presence and levels
of these microorganisms.
Statistical analysis. All data were recorded using a standardised
study form designed for this study. A gap in a sequence of
mucositis score values was filled with the same value given before
and after a gap. In case of different values before and after a gap,
the lowest value was imputed. Data were analysed using descriptive
statistics in SPSS Statistics 22 (IBM Corp., Armonk, NY, USA).
Testing for significance was done using w2 for binary outcomes
(prevalence and presence) and Mann–Whitney tests for contin-
uous outcomes. Values of Po0.05 were considered significant.
RESULTS
Demographics. In total, 64 patients were included. Statistical
analysis was done with 63 patients, as 1 patient with an acute oral
focus was not treated according to the inclusion criteria.
Demographics of patients before the onset of haematological
treatment are shown in Table 1. In the leukaemic group, 28
patients were included, of which 23 were diagnosed with AML, 4
with ALL and 1 with CML blast crisis. In the ASCT group, 35
patients were included, of which 21 were diagnosed with MM, 13
with NHL and 1 with HL. There was no statistically significant
difference between the groups regarding male/female ratio and age
(Table 1).
During the 6 weeks of follow-up after haematologic treatment, 5
of 28 leukaemic patients died. This was due to refractory disease in
1 patient, recurrence of disease in 2 patients and toxicity of
chemotherapy with subsequent complications in 2 patients, with
no contribution of oral foci. None of the ASCT patients died before
end of follow-up.
Oral foci of infection. Outcomes of dental screening are
presented in Table 1. In the leukaemic group, 24 out of 28
patients (86%) presented with chronic oral foci of infection.
Amongst them were 2 patients who had both acute and chronic
foci. In the ASCT group, 22 out of 35 patients (63%) presented
with chronic oral foci of infection. One patient had both acute and











Age mean (s.d.) 51 (12.4) 51 (10.1)
Last visit to dentist
Last 6 months 19 (68) 19 (54)
Last year 3 (11) 7 (20)
41 years ago 3 (11) 6 (17)
Not reported 3 (11) 3 (9)
Visit to dental hygienist
At least twice a year 6 (21) 8 (23)
Once a year 3 (11) 5 (14)
Never 18 (64) 21 (60)
Not reported 1 (4) 1 (3)
Oral complaintsa
No complaints 21 (75) 28 (80)
Not reported 1 (4) 0 (0)
Currently 7 (25) 7 (20)
Last 3 months 10 (36) 9 (26)
Dental status




Oral foci of infection totalb
No oral foci of infection 4 (14) 12 (34)
Acute oral foci of infection 2 (7) 2 (6)
Chronic oral foci of infection 24 (86) 22 (63)
Acute oral foci of infection
Active pus-producing fistula 1 (4) 1 (3)
Symptomatic periapical
granuloma
1 (4) 1 (3)
Chronic oral foci of infectionc
Periodontal pockets X6mm 13 (46) 11(31)
Periapical granuloma 10 (36) 10 (29)
Initial endodontic treatment 2 (7) 0 (0)
Furcation involvement 2 (7) 2 (6)
Retained roots 2 (7) 1 (3)
Fully or partially impacted teeth 3 (11) 3 (9)
Caries profunda 2 (7) 1 (3)
Follicular cyst 0 (0) 2 (6)
Periodontal condition
Healthy periodontium 0 (0) 3 (9)
Periodontal pockets X4mm 27 (96) 32 (91)
Periodontal pockets X5mm 19 (68) 21 (60)
Periodontal pockets X6mm 13 (46) 11 (31)
Periodontal status not reported 1 (4) 0 (0)
PISA score in mm2 (median, IQR)d 533 (199–834) 228 (135–478)
Plaque score (median, IQR)e,f 30% (19–50) 25% (20–50)
Bleeding score (median, IQR)e,g 45% (20–80) 20% (10–40)
Abbreviations: ASCT¼ autologous stem-cell transplantation; IQR¼ interquartile range.
Owing to rounding of the percentages, total sums are not always exactly 100%.
aTotal sums up to428 and435 patients, because some patients had both oral complaints
currently and during the last 3 months.
bTotal sums up to 428 and 435 patients, because some patients had both acute and
chronic oral foci of infection.
cTotal sums up to424 and422 patients, because some patients had more than one type
of chronic oral foci of infection.
dThe difference between the groups is significant (P¼ 0.024) using a Mann–Whitney test.
ePlaque and bleeding scores were given as an estimated percentage of the total number of
measured sites, after probing periodontal pockets.
fThe difference between the groups is not significant (P¼ 0.56) using a Mann–Whitney test.
gThe difference between the groups is significant (P¼ 0.005) using a Mann–Whitney test.
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chronic oral foci. The specific acute and chronic oral foci types are
presented in Table 1. Data on visits to the dentist and dental
hygienist and data on oral hygiene are also presented in Table 1.
The baseline median PISA and bleeding scores were significantly
higher in the leukaemic group compared with the ASCT group
(P¼ 0.024 and 0.005, respectively).
Periodontal samples. The majority of patients in this study had
periodontal infection associated with opportunistic oral pathogens.
F. nucleatum, Pa. micra, Pr. intermedia, T. forsythia and C. rectus
were isolated in 79%, 71%, 32%, 31% and 24% of patients,
respectively. Occasionally, A. actinomycetemcomitans (2%) and P.
gingivalis (5%) were isolated. No significant differences were found
between the leukaemic and the ASCT groups regarding the
prevalence of periodontal pathogens. In our study cohort, no
periodontal pathogens were cultured from any of the blood
cultures (Table 2).
Blood cultures of the leukaemic group. Blood cultures were
indicated because of neutropenic fever in all 28 leukaemic patients
(100%). Twenty-five patients (89%) had a total of 57 positive blood
cultures. The microorganisms found in the blood cultures are
presented in Table 2.
Blood cultures of the ASCT group. Blood cultures were indicated
because of neutropenic fever in 22 out of 35 ASCT patients (63%),
which is significantly lower than in the leukaemic group
(P¼ 0.0001). Out of these 22 patients, 11 (50%) had 1 or more
positive blood cultures (Table 2), which was significantly lower
than in the leukaemic group (89%; P¼ 0.002).
Chronic oral foci of infection related to various clinical
parameters. No significant differences were found between
patients with chronic oral foci of infection (N¼ 46) compared
with patients without chronic oral foci of infection (N¼ 17)
regarding positive blood cultures (P¼ 0.798), duration of neu-
tropenia (P¼ 0.066) or fever (P¼ 0.059), duration of mild
(P¼ 0.107) or severe oral mucositis (P¼ 0.398), and prevalence
of mild (P¼ 0.273) or severe oral mucositis (P¼ 0.510). Moreover,
no significant differences were found when performing a subgroup
analysis (leukaemic and ASCT). No differences were found
regarding duration of neutropenia and fever, between patients
without chronic oral foci of infection at dental screening, patients
with untreated chronic oral foci of infection and patients with
treated acute oral foci of infection.
Microorganisms found in blood culture possibly related to oral
cavity. In our study cohort, no periodontal pathogens were
initially cultured from any of the positive blood cultures
(Table 2). After specific culturing for Gram-negative aerobic rods
and staphylococci, which was done if these microorganisms were
found in positive blood cultures, one match was found between
positive blood cultures and periodontal samples for S. haemolyti-
cus. Microorganisms potentially originating from the oral cavity,
oropharynx and/or throat were found in the blood cultures of
seven patients; five leukaemic and two ASCT patients (indicated by
bold letters in Table 2). These microorganisms were not period-
ontal pathogens and were not found in any of the throat swabs.
Table 3 shows that no possible contributing factors were found
that differed significantly for the seven patients with positive blood
cultures with microorganisms possibly related to the oral cavity,
compared with the patients with positive blood cultures with
microorganisms unrelated to the oral cavity (n¼ 29). Furthermore,
four of these seven patients had oral complications during
chemotherapy unrelated to oral foci of infection (oral mucositis,
N¼ 4; herpes simplex virus, N¼ 1; and pulpitis, N¼ 1).
Neutropenia, fever and oral mucositis. A significantly higher
prevalence of severe oral mucositis (P¼ 0.014) was found amongst
leukaemic patients (57%) compared with ASCT patients (26%). No
oral mucositis was observed in 47% of the ASCT patients, which
was significantly higher than in leukaemic patients (11%;
P¼ 0.002). No significant differences were found between
leukaemic patients and ASCT patients regarding the duration
(P¼ 0.890) of severe oral mucositis. A median of 5 days was seen
in both groups. There was no relation between the severity of
mucositis and chronic oral foci of infection at baseline (P¼ 0.269).
No significant differences were found between patients with
positive blood cultures compared with patients with negative blood
cultures regarding the duration (P¼ 0.648) or prevalence of severe
oral mucositis (P¼ 0.717). However, patients with positive blood
cultures had a significantly longer duration of mild oral mucositis
than patients with negative blood cultures (P¼ 0.039). Prevalence
of mild oral mucositis was not significantly different between
patients with positive or negative blood cultures (P¼ 0.700).
Periodontal health and positive blood cultures. No significant
differences were found between patients with positive blood
cultures compared with patients with negative blood cultures
regarding periodontal inflamed surface area as measured with
PISA at baseline (P¼ 0.379). In line with this observation, patients
with positive blood cultures did not have significantly higher
plaque and bleeding scores at baseline compared with patients with
negative blood cultures (P¼ 0.338 and P¼ 0.990, respectively).
Oral complications during haematologic treatment. During
haematologic treatment, oral complications other than oral
mucositis were seen (N¼ 15; 24%; nine leukaemic and six ASCT
patients). The prevalence of exacerbation of chronic oral foci
during haematologic treatment was 4% in this study. One AML
Table 2. Microorganisms in positive blood cultures and

















S, M 17 (61%) 7 (20%)
Staphylococcus
haemolyticus
S 8 (29%) 1 (3%)
Enterococcus faecium I, S, O, E 7 (25%) 1 (3%)
Streptococcus mitis M, O, I, V, S 4 (14%) 1 (3%)
Micrococcus luteus S, E, O, OP 3 (11%) 0
Staphylococcus hominis S 3 (11%) 0
Bacillus mycoides E 0 1 (3%)
Burkholderia genus REC A E, O 1 (4%) 0
Lactobacillus rhamnosus O 1 (4%) 0
Pantoea gavinae E 1 (4%) 0
Rothia mucilaginosa OP 1 (4%) 0
Serratia marcescens S, I 1 (4%) 0
Staphylococcus aureus S, N, T, P, O 0 1 (3%)
Staphylococcus capitis S, O 1 (4%) 0
Streptococcus
parasanguinis
M, I, V, S, O 1 (4%) 0
Abbreviations: ASCT¼ autologous stem-cell transplantation; E¼ environment (plants,
animals, soil); I¼ intestines; M¼mucosal tissues; N¼ nose; O¼oral cavity; OP¼
oropharynx; P¼perineum; S¼ skin; T¼ throat; V¼ vagina. More than one microorganism
were cultured in some patients and some patients had more than one positive blood
culture, so the total sums up to 425 leukaemic and 411 ASCT patients.
aThe bold letters in this table indicate the microorganisms related to the oral cavity,
oropharynx or throat.
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patient with an acute exacerbation of an asymptomatic periapical
granuloma present at baseline and one ASCT patient with an acute
exacerbation of pre-existent gingivitis, which were both uneventful.
Oral complications not related to chronic oral foci of infection
observed were oral pain (N¼ 3), oral herpes simplex infection
(N¼ 5), peri-oral herpes simplex (N¼ 3), mandibular swelling
(N¼ 1) and oral candidiasis (N¼ 1). No significant differences
were found between patients with oral complications (N¼ 15) and
patients without oral complications (N¼ 48) regarding presence of
acute (P¼ 0.954) or chronic oral foci of infection (P¼ 0.197),
periodontal disease (pockets X6mm; P¼ 0.437), PISA score
(P¼ 0.474), smoking (P¼ 0.102), plaque scores (P¼ 0.941),
bleeding scores (P¼ 0.456), age (P¼ 0.127), positive blood cultures
(P¼ 0.453), or a significantly different duration of neutropenia
(P¼ 0.398), fever (P¼ 0.278) or severe oral mucositis (P¼ 0.214).
DISCUSSION
The results of this prospective study show that leaving chronic oral
foci of infection untreated before intensive chemotherapy and
ASCT (and during neutropenia with or without oral mucositis)
does not increase the morbidity of the cancer treatment, in
particular regarding infectious complications such as bacterial
sepsis, nor does it increase mortality.
A significantly longer median duration of neutropenia,
significantly more positive blood cultures and significantly more
severe oral mucositis were found in leukaemic patients compared
with ASCT patients. This might explain why more leukaemic
patients (18%) had positive blood cultures with microorganisms
possibly related to the oral cavity than ASCT patients (6%).
However, positive blood cultures were not associated with a
specific microorganism present in the oral cavity and the
gastrointestinal tract as assessed with cultures from periodontal
samples, throat and rectal swabs.
Comparison with previous studies. Neutropenic fever was seen in
all leukaemic patients, which corresponds with literature reporting
neutropenic fever seen in 85–97% of neutropenic episodes
(Hamalainen et al, 2008; De Rosa et al, 2013). In our study,
neutropenic fever was seen less frequently in ASCT patients (63%),
which was expected based on previous studies (39–84%) (Blanes et al,
2013; Musso et al, 2015; Zhang et al, 2015). Positive blood cultures
were found in 89% of leukaemic and 50% of ASCT patients in our
study, which is high compared with data from the literature
(Hamalainen et al, 2008; McCann et al, 2009; Eleutherakis-
Papaiakovou et al, 2010; De Rosa et al, 2013). However, comparing
our data with that from previous studies is difficult due to varying
patient groups and inconsistencies in reporting.
Instead of systemic complications of chronic oral foci, local
complications, such as interchemotherapy acute conversions of
previously diagnosed chronic dental disease, were assessed by
Toljanic et al (1999). An incidence rate of 4% was reported, which
is comparable to our data. However, both haematologic and solid
malignant neoplasms were included in Toljanic’s study, which
hampers comparison, and, more importantly, no information was
provided on blood cultures.
Bacteraemia was predominately caused by Gram-positive
bacteria in our study. In line with our results, previous studies
described a shift in time from the predominance of Gram-negative
bacteria to the predominance of Gram-positive bacteria (Horasan
et al, 2011). S. epidermidis was most often found in our positive
blood cultures (Table 2). This microorganism is a common cause
of bacteraemia and is associated with central venous catheters,
which were used in all of our patients (David et al, 2005). In
accordance with the studies by Sonis et al (2001) and McCann et al
(2009), we found that patients with oral mucositis had a
Table 3. Comparison between patients with positive blood cultures with microorganisms possibly related to the oral cavity and








unrelated to the oral
cavity (total N¼29) P-value
Baseline presence of acute oral foci of infection 0 3 0.374a
Baseline presence of chronic oral foci of infection 6 21 0.466a
Baseline presence of periodontal pockets X6mm 2 12 0.533a
Baseline presence of periapical granuloma 5 11 0.109a
Baseline presence of caries profunda 1 2 0.526a
Baseline presence of impacted teeth 2 4 0.346a





Duration of neutropenia in days 11 (7–41) 23 (8–46) 0.531
Duration of fever in days 9 (4–24) 9 (4.5–15) 0.969
Duration of severe oral mucositis in days in 17 patients with severe oral mucositis 3.5 (1.25–8), N¼4 5 (2.5–9.5), N¼13 0.477
PISA score in mm2 419.5 (94.5–1025)c 412 (142–650.75)b 1.0
Plaque scores in % 25 (10–57.5)c 30 (20–50)b 0.494
Bleeding scores in % 30 (7.5–76.25)c 30 (20–50)b 0.612
Age in years 49 (28–62) 50 (44–60) 0.969
Abbreviations: IQR¼ interquartile range; PISA¼periodontal inflamed surface area.
aResults w2 tests. All other variables were tested using Mann–Whitney tests.
bBecause of missing value, N¼ 28.
cBecause of missing value, N¼ 6.
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significantly longer duration of neutropenia and fever than
patients without oral mucositis. The first prospective study with
oral mucositis as the main objective showed severe oral
mucositis in 46% of MM patients and 42% of NHL patients
(Blijlevens et al, 2008). The lower percentage of severe oral
mucositis among ASCT patients in our study (26%) might be due
to the fact that MM patients receiving high-dose melphalan
(n¼ 21) were given ice cubes in the mouth (cryotherapy) during
chemotherapy infusion, as advised by the guidelines of MASCC/
ISOO (Lalla et al, 2014) and in other reviews (Worthington et al,
2011; Wang et al, 2015).
Microorganisms potentially originating from the oral cavity,
oropharynx and throat were found in the blood cultures of just seven
patients (Table 2). We expected the number of oral microorganisms
found in blood cultures to be higher, as even tooth brushing, a
seemingly harmless daily activity, can cause bacteraemia with oral
microorganisms (Lockhart et al, 2008). Especially in immuno-
compromised patients, as in our study, bacteraemia is expected to
occur more often and to last longer, increasing the chances of detecting
the causative microorganism by blood culturing. The patients in our
study with oral mucositis hardly brushed, but frequently rinsed the oral
cavity, which could explain the lower frequency of bacteraemia,
together with the use of SDD.
Implications. The outcomes of our study indicate that chronic
oral foci of infection without acute signs or symptoms can be left
untreated in patients receiving ASCT and/or intensive chemother-
apy. This allows for a less aggressive approach with no removal
of chronic oral foci of infection before starting chemotherapy. Such
an approach is likely to be beneficial for haematologic patients, as
removal of teeth may compromise nutrition, and malnutrition is
associated with lower quality of life (Jager-Wittenaar et al, 2011).
Tooth extraction also leads to a risk for infection, bleeding or
delayed wound healing, which may require postponing oncologic
treatment (Yamagata et al, 2006), or otherwise increase bacter-
aemia with a higher chance of septic complications. For survivors,
treatment of diseased teeth can be postponed until oncologic
treatment is completed. Moreover, pre-chemotherapy dental
workup will be less time consuming when only acute oral foci of
infection, seen ino10% of our patients, have to be treated instead
of all the chronic oral foci seen in over 70% of our patients.
Suggestions for additional research. Future prospective studies
with larger patient groups are needed, to see if leaving chronic oral foci
untreated may lead to a significantly longer duration of fever and
neutropenia, as our results showed a strong trend when comparing
duration of neutropenia (P¼ 0.066) and fever (P¼ 0.059) in patients
with and without chronic oral foci of infection. Future study methods
should enable comparison between studies, as sample size calculation
showed that over 4000 patients will be needed to find a significant
difference between patients with and without chronic oral foci of
infection, regarding positive blood cultures (respectively, 73% and 69%
of those patients had positive blood cultures in our study). The cost-
effectiveness of this less aggressive approach should be studied, and the
improvement in quality of life may be confirmed in future studies.
In conclusion, our prospective study supports the hypothesis that
chronic oral foci, if they had not exacerbated during the previous 3
months, do not have to be eliminated before intensive chemotherapy,
as they do not increase infectious complications in these patients.
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